Bibliography

Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.

If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.

Download:

 (PDF, 3MB, 220 pages) 

This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website. 

 

 

Export 87 results:
Author Title [ Type(Desc)] Year
Filters: Author is Cooper, C.  [Clear All Filters]
Journal Article
C. Garriga, Pazianas, M., Hawley, S., Delmestri, A., Prieto-Alhambra, D., Cooper, C., and Judge, A., “Oral bisphosphonate use and age-related macular degeneration: retrospective cohort and nested case-control study”, Ann N Y Acad Sci, vol. 1415, pp. 34-46, 2018.
D. Alarkawi, Ali, M. S., Bliuc, D., Pallares, N., Tebe, C., Elhussein, L., Caskey, F. J., Arden, N. K., Ben-Shlomo, Y., Abrahamsen, B., Diez-Perez, A., Pascual, J., Perez-Saez, M. J., Center, J. R., Judge, A., Cooper, C., Javaid, M. K., and Prieto-Alhambra, D., “Oral bisphosphonate use and all-cause mortality in patients with moderate-severe (grade 3B-5D) chronic kidney disease: a population-based cohort study”, J Bone Miner Res, 2020.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
G. Breart, Cooper, C., Meyer, O., Speirs, C., Deltour, N., and Reginster, J. Y., “Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database”, Osteoporos Int, vol. 21, pp. 1181-7, 2010.
D. J. Torgerson, Sykes, D., Puffer, S., Brown, P., and Cooper, C., “Pharmaceutical treatment of symptomatic vertebral fractures in primary care”, Ann Rheum Dis, vol. 63, pp. 853-6, 2004.
T. P. van Staa, Leufkens, H., Abenhaim, L., and Cooper, C., “Postmarketing surveillance of the safety of cyclic etidronate”, Pharmacotherapy, vol. 18, pp. 1121-8, 1998.
A. Judge, Garriga, C., Arden, N. K., Lovestone, S., Prieto-Alhambra, D., Cooper, C., and Edwards, C. J., “Protective effect of antirheumatic drugs on dementia in rheumatoid arthritis patients”, Alzheimers Dement (N Y), vol. 3, pp. 612-621, 2017.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
F. de Vries, de Vries, C., Cooper, C., Leufkens, B., and van Staa, T. P., “Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database”, Int J Epidemiol, vol. 35, pp. 1301-8, 2006.
A. Lalmohamed, de Vries, F., Bazelier, M. T., Cooper, A., van Staa, T. P., Cooper, C., and Harvey, N. C., “Risk of fracture after bariatric surgery in the United Kingdom: population based, retrospective cohort study”, Bmj, vol. 345, p. e5085, 2012.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., and de Vries, F., “Risk of fracture in patients with Charcot-Marie-Tooth disease”, Muscle Nerve, vol. 50, pp. 919-24, 2014.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Staa, T. P., and de Vries, F., “Risk of fracture in patients with Guillain-Barre syndrome”, Osteoporos Int, vol. 25, pp. 1845-51, 2014.
M. T. Bazelier, Van Staa, T., Uitdehaag, B. M., Cooper, C., Leufkens, H. G., Vestergaard, P., Bentzen, J., and de Vries, F., “The risk of fracture in patients with multiple sclerosis: the UK general practice research database”, J Bone Miner Res, vol. 26, pp. 2271-9, 2011.
S. Pouwels, de Boer, A., Leufkens, H. G., Weber, W. E., Cooper, C., van Onzenoort, H. A., and de Vries, F., “Risk of fracture in patients with muscular dystrophies”, Osteoporos Int, vol. 25, pp. 509-18, 2014.
S. Pouwels, Bazelier, M. T., de Boer, A., Weber, W. E., Neef, C., Cooper, C., and de Vries, F., “Risk of fracture in patients with Parkinson's disease”, Osteoporos Int, vol. 24, pp. 2283-90, 2013.
E. Martin-Merino, Petersen, I., Hawley, S., Alvarez-Gutierrez, A., Khalid, S., Llorente-Garcia, A., Delmestri, A., Javaid, M. K., van Staa, T. P., Judge, A., Cooper, C., and Prieto-Alhambra, D., “Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK”, Osteoporos Int, vol. 29, pp. 467-478, 2018.
D. E. Robinson, Ali, M. S., Pallares, N., Tebe, C., Elhussein, L., Abrahamsen, B., Arden, N. K., Ben-Shlomo, Y., Caskey, F. J., Cooper, C., Dedman, D., Delmestri, A., Judge, A., Perez-Saez, M. J., Pascual, J., Nogues, X., Diez-Perez, A., Strauss, V. Y., Javaid, M. K., and Prieto-Alhambra, D., “Safety of oral bisphosphonates in moderate-to-severe chronic kidney disease: a bi-national cohort analysis”, J Bone Miner Res, 2020.
R. Y. van der Velde, Wyers, C. E., Curtis, E. M., Geusens, P., van den Bergh, J. P. W., de Vries, F., Cooper, C., van Staa, T. P., and Harvey, N. C., “Secular trends in fracture incidence in the UK between 1990 and 2012”, Osteoporos Int, vol. 27, pp. 3197-3206, 2016.
F. de Vries, van Staa, T. P., Bracke, M. S., Cooper, C., Leufkens, H. G., and Lammers, J. W., “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
T. P. van Staa, Geusens, P., Pols, H. A., de Laet, C., Leufkens, H. G., and Cooper, C., “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
M. T. Bazelier, van Staa, T. P., Uitdehaag, B. M., Cooper, C., Leufkens, H. G., Vestergaard, P., Bentzen, J., and de Vries, F., “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
K. T. Palmer, D'Angelo, S., Harris, E. C., Linaker, C., Sayer, A. A., Gale, C. R., Evandrou, M., Van Staa, T., Cooper, C., and Coggon, D., “Sleep disturbance and the older worker: findings from the Health and Employment after Fifty study”, Scand J Work Environ Health, vol. 43, pp. 136-145, 2017.
E. Burn, Edwards, C. J., Murray, D. W., Silman, A., Cooper, C., Arden, N. K., Pinedo-Villanueva, R., and Prieto-Alhambra, D., “Trends and determinants of length of stay and hospital reimbursement following knee and hip replacement: evidence from linked primary care and NHS hospital records from 1997 to 2014”, BMJ Open, vol. 8, p. e019146, 2018.
R. Y. van der Velde, Wyers, C. E., Teesselink, E., Geusens, P., van den Bergh, J. P. W., de Vries, F., Cooper, C., Harvey, N. C., and van Staa, T. P., “Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: Variation by age, sex, geographic location and ethnicity”, Bone, vol. 94, pp. 50-55, 2017.
T. Van Staa, Abenhaim, L., and Cooper, C., “Upper gastrointestinal adverse events and cyclical etidronate”, Am J Med, vol. 103, pp. 462-7, 1997.
T. P. van Staa, Abenhaim, L., Cooper, C., Zhang, B., and Leufkens, H. G., “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
P. C. Souverein, van Staa, T. P., Egberts, A. C., De la Rosette, J. J., Cooper, C., and Leufkens, H. G., “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
F. de Vries, Souverein, P. C., Cooper, C., Leufkens, H. G., and van Staa, T. P., “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
T. P. van Staa, Abenhaim, L., and Cooper, C., “Use of cyclical etidronate and prevention of non-vertebral fractures”, Br J Rheumatol, vol. 37, pp. 87-94, 1998.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
T. P. van Staa, Cooper, C., Leufkens, H. G., Lammers, J. W., and Suissa, S., “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Zhang, B., and Cooper, C., “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
T. P. van Staa, Leufkens, H. G., Abenhaim, L., Begaud, B., Zhang, B., and Cooper, C., “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
P. C. Souverein, Berard, A., van Staa, T. P., Cooper, C., Egberts, A. C., Leufkens, H. G., and Walker, B. R., “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
T. P. van Staa, Wegman, S., de Vries, F., Leufkens, B., and Cooper, C., “Use of statins and risk of fractures”, Jama, vol. 285, pp. 1850-5, 2001.
T. P. van Staa, Leufkens, H. G., and Cooper, C., “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
[Page last reviewed 4 February 2021]